Pregnancy Registry: If you become pregnant while taking Topiramate, talk to your healthcare provider about registering with the North American Antiepileptic Drug Pregnancy Registry
10 Weight Management / Obesity We have already discussed how the GLP-1 hormone affects appetite, fullness and other metabolic processes
Advice for Healthcare Professionals The MHRA Drug Safety Update provides the following key guidance for healthcare professionals: Semaglutide treatment may be very rarely associated with NAION, which can cause vision loss, typically in one eye NAION typically presents as sudden, painless vision loss described as blurring or cloudiness Privately prescribed semaglutide may not appear on a patients medical record if a patient presents with these symptoms, enquire about semaglutide use Patients reporting sudden loss of vision (including partial loss) should be urgently referred for specialist examination by an ophthalmologist Discontinue semaglutide treatment if NAION is confirmed Advise new patients, or existing patients during medication reviews, to urgently attend eye casualty or A&E if they experience sudden vision loss or rapidly worsening eyesight An alert advised healthcare professionals to be vigilant for further issues, including rare but serious side effects such as acute pancreatitis
Should you have any concerns about the integrity of your semaglutide, it's best to always err on the side of caution
You may need a different drug other than semaglutide If youre not losing weight on semaglutide, its possible the drug simply isnt the right fit for you
